vanoxerine has been researched along with MPTP Neurotoxicity Syndrome in 7 studies
vanoxerine: structure given in first source
vanoxerine : An N-alkylpiperazine that consists of piperazine bearing 2-bis(4-fluorophenyl)methoxy]ethyl and 3-phenylpropyl groups at positions 1 and 4 respectively. Potent, competitive inhibitor of dopamine uptake (Ki = 1 nM for inhibition of striatal dopamine uptake). Has > 100-fold lower affinity for the noradrenalin and 5-HT uptake carriers. Also a potent sigma ligand (IC50 = 48 nM). Centrally active following systemic administration.
| Excerpt | Relevance | Reference |
|---|---|---|
| " All TaClo derivatives showed significant cytotoxicity in all cell lines after 72 hours with the following rank order of toxic potency: 1-Tribromomethyl-1,2,3,4-tetrahydro-beta-carboline (TaBro) > TaClo > MPP(+) > 1,2,3,4-tetrahydro-beta-carboline (THbetaC) > 2[N]-methyl-TaClo > 2[N]-methyl-THbetaC." | 1.33 | Cytotoxicity of chloral-derived beta-carbolines is not specific towards neuronal nor dopaminergic cells. ( Bringmann, G; Brückner, R; Feineis, D; Hwang, YI; Ott, S; Schwarz, J; Storch, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schlüter, OM | 1 |
| Fornai, F | 3 |
| Alessandrí, MG | 1 |
| Takamori, S | 1 |
| Geppert, M | 1 |
| Jahn, R | 1 |
| Südhof, TC | 1 |
| Koga, K | 1 |
| Mori, A | 1 |
| Ohashi, S | 1 |
| Kurihara, N | 1 |
| Kitagawa, H | 1 |
| Ishikawa, M | 1 |
| Mitsumoto, Y | 1 |
| Nakai, M | 1 |
| Storch, A | 1 |
| Hwang, YI | 1 |
| Bringmann, G | 1 |
| Feineis, D | 1 |
| Ott, S | 1 |
| Brückner, R | 1 |
| Schwarz, J | 1 |
| Vaglini, F | 2 |
| Fascetti, F | 2 |
| Maggio, R | 1 |
| Corsini, GU | 2 |
| Tedeschi, D | 1 |
| Cavalletti, M | 1 |
| González-Polo, RA | 1 |
| Mora, A | 1 |
| Clemente, N | 1 |
| Sabio, G | 1 |
| Centeno, F | 1 |
| Soler, G | 1 |
| Fuentes, JM | 1 |
| Johannessen, JN | 1 |
| Markey, SP | 1 |
7 other studies available for vanoxerine and MPTP Neurotoxicity Syndrome
| Article | Year |
|---|---|
Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; alpha-Synuclein; Animals; Antibodies; | 2003 |
H MRS identifies lactate rise in the striatum of MPTP-treated C57BL/6 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blotting, Western; Brain Chemistry; Chromatog | 2006 |
Cytotoxicity of chloral-derived beta-carbolines is not specific towards neuronal nor dopaminergic cells.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Brain Neoplasms; Carbolines; Cell Line, Tumor; Cell Survival; | 2006 |
(+)MK-801 prevents the DDC-induced enhancement of MPTP toxicity in mice.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Ditiocarb; Dizocilpine Maleate | 1994 |
Striatal MPP+ levels do not necessarily correlate with striatal dopamine levels after MPTP treatment in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Acetaldehyde; Animals; Ch | 1996 |
Mechanisms of MPP(+) incorporation into cerebellar granule cells.
Topics: 1-Methyl-4-phenylpyridinium; Amino Acid Transport Systems, Basic; Amino Acids, Basic; Animals; Anima | 2001 |
Characterization of 1-methyl-4-[4'-amino]phenyl-1,2,3,6-tetrahydropyridine toxicity in the mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Dopamine; Male; Mice; | 1990 |